• Medtronic received CE Mark for its Vitalis pacemaker portfolio, designed for conduction system pacing.
• The portfolio’s ReSyncra CSP offers a treatment option for patients in whom effective conventional cardiac resynchronization therapy cannot be achieved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.